Artiva Biotherapeutics (ARTV) Proxy Filing summary

Executive summary

• Annual Meeting scheduled for June 24, 2025, to be held virtually for all stockholders of record as of April 25, 2025.

• Three key proposals: election of a Class I director, ratification of KPMG LLP as auditor, and approval of an amendment to the 2024 Equity Incentive Plan.

• Proxy materials and annual report are available online, and multiple voting methods are provided.

Voting matters and shareholder proposals

• Proposal 1: Elect Daniel Baker, Ph.D., as Class I director until 2028.

• Proposal 2: Ratify KPMG LLP as independent auditor for fiscal year ending December 31, 2025.

• Proposal 3: Approve amendment to 2024 Equity Incentive Plan, increasing authorized shares by 1,214,580.

• Board recommends voting FOR all proposals.

• Stockholders may submit proposals for the 2026 meeting by specified deadlines and procedures.

Board of directors and corporate governance

• Board consists of nine members divided into three classes with staggered three-year terms.

• Board leadership is separated: Brian Daniels, M.D., serves as independent Chair; CEO and Chair roles are distinct.

• Board committees include Audit, Compensation, Nominating and Corporate Governance, Clinical Strategy, Philanthropic, and Technical Operations.

• Majority of directors are independent per Nasdaq standards; diversity and relevant expertise are emphasized.

• Regular executive sessions are held with only independent directors.